| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Genetics, Vol. 178, 737-748, February 2008, Copyright © 2008
doi:10.1534/genetics.107.081679
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


* Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544 and
Department of Genetics, Case Western Reserve University, Cleveland, Ohio 44106-4955
2 Corresponding author: Lewis Thomas Labs, Washington Rd., Princeton University, Princeton, NJ 08544.
E-mail: pschedl{at}princeton.edu
| ABSTRACT |
|---|
|
|
|---|
Previous reports have indicated that fl(2)d is necessary for regulating the alternative splicing of multiple pre-mRNA targets. In addition to its role directing Sxl splicing in females, fl(2)d also functions at the next step in the sex determination hierarchy by regulating the female-specific splicing of tra (GRANADINO et al. 1996; ORTEGA et al. 2003). In addition, fl(2)d is required in both sexes, outside of the sex determination pathway, for regulating the alternative splicing of Ultrabithorax (Ubx) (BURNETTE et al. 1999). Remarkably, each of the three known fl(2)d targets are alternatively spliced via three distinct mechanisms. Female-specific Sxl splicing is accomplished by skipping an entire exon in Sxl pre-mRNAs by blocking that exon's 5' and 3' splice sites. By contrast, an alternative 3' splice site is used to produce female-spliced tra mRNA, most likely by a process in which the default 3' splice site is blocked and the female-specific 3' splice site is activated (SOSNOWSKI et al. 1989; VALCARCEL et al. 1993; DESHPANDE et al. 1999). In yet a third alternative splicing paradigm, it is thought that fl(2)d promotes the inclusion of the small internal exons mI and mII of Ubx as fewer mature mRNAs contain these exons in animals compromised for fl(2)d. Since each of the three pre-mRNAs are processed in three different fashions, it is clear that fl(2)d's function is not limited to a specific alternative splicing event.
Much of the evidence demonstrating that Fl(2)d regulates splicing comes from experiments done in Drosophila. In support of an evolutionarily conserved role for fl(2)d in splicing regulation, one of its homologs, Wilms'-tumor-1-associated protein (WTAP) has been isolated from human spliceosomes (ZHOU et al. 2002). Despite an abundance of evidence indicating that fl(2)d regulates pre-mRNA splicing, it has been difficult to elucidate a molecular mechanism that explains exactly how fl(2)d contributes to the alternative splicing process. Here we attempt to address this question by analyzing the ability of Fl(2)d protein to associate with general splicing regulators that have a clearly defined function in the splicing process. We have found that Fl(2)d interacts both genetically and physically with the early acting general splicing regulators Snf, U170K, U2AF50, and U2AF38, but does not interact with the later-acting general splicing regulators U540K or SKIP. We also performed a detailed analysis of the Sxl/Fl(2)d protein–protein interaction and provide evidence supporting a model whereby Sxl functions during the early stages of spliceosome assembly, rather than during the first and second catalytic steps, to regulate alternative splicing events.
| MATERIALS AND METHODS |
|---|
|
|
|---|
E18, and the following transgenic alleles were used: P{w+, snf5mer}, P{w+, otu::Sxl}, and the deficiency Df 2RCX1 (Bloomington Stock Center).
Antibodies:
anti-Sxl m104 (1:10), anti-Sxl m114 (1:10), mouse anti-β-GAL (1:10) (Developmental Studies Hybridoma Bank, Iowa City, IA), anti-Snf 4G3 (1:10) (FLICKINGER and SALZ 1994), anti-Scute5A10 (1:10) (DESHPANDE et al. 1995), anti-U1-70K (1:6000) (NAGENGAST et al. 2003), anti-U2AF50 (1:5000–50,000) (RUDNER et al. 1998), anti-U2AF38 (1:10,000) (RUDNER et al. 1996), anti-SKIPAb57 (1:2500) (ZHANG et al. 2003), anti-U5-40k (1:50,000) (ACHSEL et al. 1998), anti-U5-116k (1:50,000) (FABRIZIO et al. 1997). Monoclonal line anti-Fl(2)d 9G2 was generated similarly to that described by DESHPANDE et al. (1995) and used at a dilution of 1:10. His-tagged full-length Fl(2)d protein was produced using a baculovirus expression vector (a generous gift from Angeles Ortega) and purified on a Ni-NTA agarose column (QIAGEN, Valencia, CA).
Immunohistochemistry:
Embryos were fixed and stained as described previously (DESHPANDE et al. 1995). Alexa fluorophore-conjugated secondary antibodies were used at a 1:500 dilution (Invitrogen, San Diego). Hoechst was used to visualize DNA (1:1000, 5–10 min at room temperature).
Immunoprecipitations:
Nuclear embryonic extract was prepared similar to SAMUELS et al. (1994). Ovarian extract was prepared by dissecting ovaries from 20 females and following closely the protocol described by TAN et al. (2001). After two freeze/thaw cycles, the unfiltered ovarian extract was centrifuged twice at 3000 rpm for 5 min. For immunoprecipitations (TAN et al. 2001), extracts were incubated with 400 µl immunoprecipitation (IP) buffer, RNAsin, and 10–20 µl protein A/G beads crosslinked to the appropriate antibodies. Experiments with embryonic extract were carried out overnight at 4° or for 1–2 hr at room temperature and experiments with ovarian extract were carried out for 30 min at 29°. Beads were washed four to five times with 1 ml IP buffer, boiled in SDS/PAGE sample buffer for 5–10 min, and used in SDS/PAGE and Western blot analysis. (For all ovarian and embryonic extract preparations used in immunoprecipitation experiments, protein inhibitors were increased 10- to 40-fold to prevent Fl(2)d proteolysis.) GST pull-down experiments were performed as described previously (CHAOUKI and SALZ 2006). In vitro immunoprecipitation experiments were performed as described by DESHPANDE et al. (1996). Expression and purification of recombinant full-length Sxl protein and GST-tagged Sxl fragments was described in SAMUELS et al. (1998). Expression and purification of Fl(2)d protein is described above.
| RESULTS |
|---|
|
|
|---|
100-aa N-terminal domain. Truncated Sxl proteins that lack 40 aa in the N terminus are defective in Sxl and tra splicing (YANOWITZ et al. 1999). Conversely, a transgene that expresses a chimeric protein, Nβ-gal, consisting of the first 99 aa of Sxl fused to β-galactosidase, behaves like a dominant negative (DESHPANDE et al. 1999). In wild-type females, the Nβ-gal transgene interferes with Sxl autoregulation and causes partial female lethality. This lethality can be dominantly enhanced by reducing the dose of the Sxl gene or by mutations in known cofactors such as the U1/U2 snRNP protein Snf. To identify other genes involved in Sxl autoregulation, we screened the stock center deficiency kits for deletions that, when trans to the Nβ-gal transgene, either enhanced or suppressed its female lethal effects. One of deficiencies that suppressed the lethal effects of the Nβ-gal transgene was Df(2R)CX1. The interacting gene was identified as fl(2)d using smaller deficiencies and then by testing mutations in candidate genes that map to this region. Table 1 shows that female progeny from Nβ-gal/+ females and Nβ-gal/Nβ-gal males are only 87.9% as viable as their male siblings. fl(2)d1 suppressed this lethality as female progeny from fl(2)d1/+; Nβ-gal/+ females and Nβ-gal/Nβ-gal males are just as viable as their male counterparts. Similar results were obtained for the fl(2)d2 allele (data not shown).
|
60 aa), and presumably nonfunctional, polypeptide (PENALVA et al. 2000). We tested for genetic interactions by crossing females heterozygous for either fl(2)d1 or fl(2)d2 to Sxl– males. In these crosses, half of the progeny inherit the fl(2)d mutation and all of the progeny are maternally compromised for fl(2)d. Furthermore, since Sxl is on the X chromosome, all female progeny are heterozygous for Sxl. A reduced maternal dose of general splicing factors critical for the alternative splicing of Sxl pre-mRNAs, combined with half the normal zygotic dose of Sxl, can compromise the activation of the Sxl autoregulatory loop in early embryos, which results in female-specific lethality (NAGENGAST et al. 2003). As shown in Table 2, we found that when mothers are heterozygous for the apparent null mutation, fl(2)d2, there is a small reduction (87%) in the viability of Sxl7B0/+ females compared to their male siblings. Since the protein null allele had only a mild effect on female viability, a strong maternal effect for the temperature-sensitive fl(2)d1 allele was not anticipated. However, contrary to this expectation, we found that fl(2)d1/+ females crossed to Sxl7BO/+ males gave rise to female progeny that were only 65% as viable as their male counterparts. Since fl(2)d1 is stronger than the null allele in this genetic test, this result suggests that fl(2)d1 is antimorphic.
|
80 kDa (PENALVA et al. 2000), in total extracts from adult males and females and from embryos. A protein of a similar size is also detected in nuclear extracts; however, Fl(2)d is quite sensitive to proteolysis and in some nuclear extract preparations a smaller
60-kDa protein is observed. To confirm the specificity of our monoclonal antibody, we used it to probe whole mounts of wild-type and fl(2)d2 embryos. The Fl(2)d protein localizes to the nucleus in wild-type embryos (Figure 1B, arrowhead), while it cannot be detected in homozygous fl(2)d2 embryos (Figure 1B, arrow). Figure 1C shows that Fl(2)d is not distributed uniformly throughout the nucleus but instead is concentrated in specific subregions as has been reported for other splicing factors.
|
|
Although these findings implicate the Sxl R1 RRM domain in protein–protein interactions with Fl(2)d, we wondered whether the Sxl N-terminal domain might also contribute to stabilizing the physical interactions between these two proteins. For one, the Fl(2)d protein interacted only poorly with a GST fusion protein containing a single R1 RRM domain (data not shown). In addition, one possible explanation for why a reduction in fl(2)d activity suppresses the female lethal effects of the Nβ-gal transgene is that the Fl(2)d protein binds to the Sxl Nβ-GAL fusion protein and recruits it to Sxl pre-mRNA splicing complexes. In this scenario, the female lethal effect of the transgene would be suppressed because less of the dominant-negative Nβ-GAL fusion protein would be incorporated into Sxl pre-mRNA splicing complexes when the activity of Fl(2)d is reduced. To explore this possibility, we tested whether the Fl(2)d can interact with the Sxl N terminus in vitro. In the experiment in Figure 2D, beads containing Fl(2)d antibody were used to pull down a GST-Sxl N-terminal fusion protein. When Fl(2)d was included in the incubation mix, a small amount of the GST-Sxl N-terminal protein could be pulled down by the Fl(2)d antibody beads, while the fusion protein was not pulled down when Fl(2)d was omitted from the incubation mix. While this finding would support the idea that the female lethal effects of the Nβ-GAL fusion protein might depend upon physical interactions with Fl(2)d, we were unable to demonstrate similar Nβ-GAL-Fl(2)d complexes in ovarian extracts from Nβ-gal transgenic females.
Sxl and Fl(2)d are associated in a protein complex in fl(2)d1 ovaries:
One model that could explain the apparent antimorphic activity of fl(2)d1 is that the aspartic-acid-to-asparagine substitution in the mutant protein disrupts Fl(2)d-Sxl protein interactions. If that is the case, Fl(2)d-Sxl complexes might not be formed or might be unstable in fl(2)d1 mutant females. Since fl(2)d1 females that survive at the permissive temperature are sterile, it is not possible to obtain a population of homozygous fl(2)d1 embryos. However, we thought that it would be possible to test for complexes with the mutant Fl(2)d1 protein in ovarian extracts. For this purpose, we raised fl(2)d1 flies at the permissive temperature. Following eclosion, we shifted the adults to 29° for 2–4 days. At the restrictive temperature, Sxl splicing in the mutant ovaries is in the male mode and little or no Sxl protein is expressed. To circumvent this problem, we rescued Sxl protein expression in the germline of the fl(2)d1 females by driving the expression of a female Sxl cDNA with the germline-specific otu promoter (P{w+, otu::Sxl}) (HAGER and CLINE 1997).
As shown in Figure 3A, wild-type ovarian extracts differ from extracts of embryos or adults in that two protein species are recognized by the Fl(2)d antibody. One is the same size,
80 kDa, as that observed in embryonic and adult extracts while the other is slightly larger. We suspect that this larger protein species is either a modified form of Fl(2)d or the product of an alternatively spliced fl(2)d transcript because we find that both proteins are present in Sxl immunoprecipitates from wild-type ovaries (Figure 3B). As shown in Figure 3C, both proteins are also present in Sxl immunoprecipitates from fl(2)d1 mutant ovaries. With the caveat that there may be small differences in the yield of the wild-type and Fl(2)d1 mutant complexes, this finding indicates that Fl(2)d1 protein is capable of assembling into a complex with Sxl. If there is no defect in the Fl(2)d-Sxl complex assembly, this would argue that Fl(2)d1 protein interferes with the splicing activity of the Sxl protein at a subsequent step in the splicing reaction.
|
Since fl(2)d mutations enhance the female lethal effects of snf, we decided to test whether Fl(2)d is found in a complex with Snf as is observed for Sxl. We immunoprecipitated embryonic nuclear extracts with Snf antibody and then probed Western blots of the precipitated proteins with Fl(2)d antibody. Figure 4A shows that Fl(2)d is present in Snf immunoprecipitates. Given that the Sxl-Snf complex is unstable in the absence of RNA, while the Sxl-Fl(2)d complex is not, we tested whether RNase treatment disrupts the Fl(2)d-Snf complex in embryonic nuclear extracts. Like the Fl(2)d-Sxl complex, we found that the Fl(2)d-Snf complex is RNA independent. However, unlike the complex with Sxl, we did not see an enrichment of Fl(2)d in RNAse-treated extracts relative to extracts treated with an RNAse inhibitor (Figure 4A).
|
snf148 encodes a form of the Snf protein that can assemble into a U2 but not a U1 snRNP. Unlike wild-type Snf, the mutant Snf148 protein is also defective in its interaction with the Sxl protein, and little or no Sxl-Snf148 complexes are detected (NAGENGAST et al. 2003). Consistent with this defect in Sxl-Snf interactions, when snf148/+ females are crossed to Sxl– males, the female progeny are only 48% as viable as their male siblings (Table 2). The antimorphic fl(2)d1 allele enhances the female lethality of snf148 mutation and daughters arising from snf148/+; fl(2)d1/+ mothers and Sxl– fathers are only 11% as viable as their male counterparts (Table 2). By contrast, the null allele fl(2)d2 did not show any interaction with snf148.
snf5mer is the reciprocal allele to snf148 in that it encodes a form of Snf that assembles into U1 but not U2 snRNPs (STITZINGER et al. 1999). Moreover, unlike snf148, the Snf5mer protein can form a complex with Sxl and seems to have less of an effect on Sxl-dependent alternative splicing (NAGENGAST et al. 2003). As can be seen in Table 2, female progeny from snfJ210/+ ; +/+; P{w+, snf5mer}/+ mothers and Sxl– fathers are equally as viable as males. On the other hand, we detected a synergistic interaction between fl(2)d1 and snf5mer as snfJ210/+ ; fl(2)d1/+; P{w+, snf5mer}/+ females crossed to Sxl– males gave rise to females that were only 16% as viable as their male siblings. fl(2)d2 also interacted with the U2-defective snf5mer mutation; however, the effects were significantly weaker as the corresponding female progeny were 79% as viable (Table 2).
Since the mutant Snf148 and Snf5mer proteins exhibit differences in their ability to interact with the U1 and U2 snRNPs and with Sxl, we wondered whether they also differed in their ability to interact with Fl(2)d. In the experiments in Figure 4B, extracts prepared from wild-type, snf148, and snf5mer mutant embryos were immunoprecipitated with Snf antibody. We then probed Western blots of the immunoprecipitated proteins with Fl(2)d antibodies. Since we were able to detect Fl(2)d in all three Snf immunoprecipitates, it would appear that both snf148 and snf5mer are able to assemble into complexes containing Fl(2)d protein. On the other hand, it would appear that the Snf5mer:Fl(2)d complex is partially destabilized relative to wild type as it was generally more difficult to detect Fl(2)d in the Snf5mer immunoprecipitates than in the wild-type or Snf148 immunoprecipitates.
fl(2)d shows genetic interactions with U2-associated factor U2AF:
The fact that the U2-defective snf5mer shows female lethal interactions with fl(2)d even though snf5mer/+ results in little or no female lethality on its own suggests that one of the critical Fl(2)d-Snf interactions in the regulation of alternative splicing by Sxl is likely to involve the U2 snRNP. That this might correspond to a function of the U2 snRNP at a step early in the splicing reaction is suggested by the finding that the antimorphic fl(2)d1 allele enhances female lethal effects of the U1-defective snf148. To test these ideas further, we assayed for interactions between fl(2)d and other proteins that are associated or that function with either the U1 or the U2 snRNPs.
The U2-associated factor U2AF functions to recruit the U2 snRNP to the 3' splice junction and is composed of two different subunits, U2AF38 and U2AF50 (REED 2000). To look for genetic interactions between fl(2)d and U2AF, we tested whether reducing U2AF activity has female lethal effects. For this purpose, females heterozygous for a mutation in the U2AF38 subunit, U2AF38
E18 (RUDNER et al. 1996), were mated with Sxl– males. As shown in Table 2, a reduction in the maternal contribution of U2AF38 had no apparent effect on the viability of the Sxl–/+ female progeny from this cross. However, as found for the U2-defective snf5mer mutation, female lethal interactions were observed when the mothers were simultaneously heterozygous for U2AF38
E18 and fl(2)d1. Female progeny from fl(2)d1/U2AF38
E18 mothers and Sxl– fathers were only 25% as viable as their sibling males (Table 2). As seen for snf5mer, U2AF38
E18 does not enhance the female lethal effects of the null mutation fl(2)d2 as strongly as it does the presumed antimorph fl(2)d1.
Fl(2)d associates with U1-70k and U2AF:
The genetic experiments described above suggest that Fl(2)d functions at a point early in the splicing reaction through interactions with proteins that function at the 5' and perhaps also at the 3' splice sites. The results of these genetic experiments are supported by the finding that Fl(2)d forms complexes with the U1 and the U2 snRNP protein Snf in nuclear extracts. To provide additional evidence for a physical association between Fl(2)d and factors important for the assembly or functioning of the U1 and U2 snRNPs, we immunoprecipitated wild-type nuclear extracts with Fl(2)d antibody and then assayed for the presence of U1- or U2-associated factors. Figure 5 shows that the U1-snRNP protein U1-70k is present in Fl(2)d immunoprecipitates, but absent from the negative control Scute immunoprecipitates. In addition, both subunits of U2AF, U2A50 and U2AF38, were present in Fl(2)d immunoprecipitates (Figure 5). These results provide additional evidence for a physical association between Fl(2)d and proteins that act at both the 5' and the 3' splice sites. Furthermore, these results support the idea that the function of Fl(2)d in Sxl-dependent regulation of alternative splicing occurs at an early step in the splicing reaction.
|
|
Fl(2)d does not associate with SKIP:
We also tested whether Fl(2)d is associated in an immunoprecipitable complex with the SKIP protein. SKIP is a late-acting splicing factor that has been found in B and C, but not in A, spliceosomal complexes (HARTMUTH et al. 2002; JURICA et al. 2002; MAKAROV et al. 2002; DECKERT et al. 2006). It then remains associated with the spliceosome through both the first and the second catalytic steps. As observed for U5-40k, we did not detect SKIP in the Fl(2)d immunoprecipitates from embryonic nuclear extracts, while U2AF50 was present (Figure 6A). Reciprocal SKIP immunoprecipitation experiments were consistent with these results (data not shown).
Sxl does not associate with either U5-40k or SKIP:
The results presented above indicate that Fl(2)d is associated with splicing complexes that are present during the early stages of spliceosome assembly, but does not seem to be in complexes that are formed during the actual catalytic splicing reaction. An important question is whether the Sxl protein is also primarily associated with complexes involved in the initial assembly of the U1 and U2 snRNPs on the pre-mRNA or remains present during the conversion of the A complex to the activated B complex. To address this question, we immunoprecipitated embryonic nuclear extracts with Sxl antibodies and then tested for the presence of U5-40k and SKIP proteins. As shown in Figure 6A, neither U5-40k nor SKIP could be detected in Sxl immunoprecipitates even though both U2AF50 and Fl(2)d could be detected in the same Sxl immunoprecipitations. Likewise, in the reciprocal IP with the U5-40k antibody, Sxl could not be detected, but U2AF50, Snf, and U5-116k were present (Figure 6A and data not shown).
Similar results were obtained in GST pull-down experiments from nuclear extracts using a GST-Sxl fusion protein. As shown in Figure 6B, GST-Sxl can pull down the Snf protein from nuclear extracts, while Snf is not pulled down by GST alone. In contrast, the SKIP protein is not pulled down by either GST-Sxl or GST. To test whether SKIP can be pulled down from nuclear extracts with a GST fusion protein, we generated a GST fusion to the U2 snRNP protein U2A'. As shown in Figure 6B, SKIP and also Snf can be pulled from nuclear extracts by the GST-U2A' fusion protein. Taken together, these results suggest that, like Fl(2)d, Sxl is associated with splicing complexes that are formed during the early steps in the splicing reaction, while it does not remain associated with complexes that are present during the later stages of splicing.
| DISCUSSION |
|---|
|
|
|---|
Several lines of evidence suggest that this is also likely to be true for Fl(2)d. First, we found that Fl(2)d is in an immunoprecipitable complex with Snf, U1-70K, and both of the U2AF subunits, U2AF50 and U2AF38. All of these proteins are expected to be present in one or more of the complexes (E, A, or B) that are formed early in the splicing reaction. Second, it has recently been found that U2AF not only is present in the early complexes E and A, but also can be detected in the inactive B complex (DECKERT et al. 2006). Consistent with this expectation, we were able to detect complexes between U2AF50 and the U5 snRNP protein U5-40k. On the other hand, while we could detect complexes between U2AF50 and Fl(2)d, we could not detect complexes between U5-40k and Fl(2)d. This finding would suggest that Fl(2)d is stably associated with the E and/or A complex, but is not stably associated with the B complex. Third, the SKIP protein associates with the inactive and activated B complexes, but is absent from the A complex (JURICA and MOORE 2003; DECKERT et al. 2006). As was the case for U5-40k, we could not detect interactions between SKIP and Fl(2)d. With the caveat that these negative results must be interpreted with caution, these findings, taken together, would argue that Fl(2)d functions at an early step(s) in the splicing reaction prior to the formation of complex B.
Since Fl(2)d is expressed in both sexes and has functions in alternative splicing that are not connected to Sxl, it could be argued that the physical interactions detected between Fl(2)d and different components of the splicing apparatus do not reflect its functioning in Sxl-dependent alternative splicing. While this is a potential concern, there are a number of reasons why we believe this to be unlikely. For one, these complexes appear to be physiologically relevant to Sxl-dependent alternative splicing as we observe female-specific genetic interactions between fl(2)d and the genes encoding several of these proteins. In the case of snf, we tested not only a null allele, but also two mutations, snf148 and snf5mer, which differentially affect Snf protein interactions with the U1 or the U2 snRNPs, respectively. When mothers heterozygous for the U1-deficient snf148 are mated to Sxl– fathers, there is a marked reduction in the viability of female offspring. This female lethality is enhanced by the antimorphic allele fl(2)d1, but not by the null allele fl(2)d2. In contrast to snf148, there is little, if any, female-specific lethality in the progeny of snf5mer/+ females and Sxl– fathers; however, the snf5mer allele shows a very strong synergistic female lethal interaction with fl(2)d1. Likewise, a strong synergistic interaction was observed between fl(2)d1 and U2AF38
E18.
Another reason to believe that the association of Fl(2)d with early splicing regulators is relevant to how it promotes Sxl-dependent alternative splicing is the fact that Sxl is found in complexes with the same set of splicing factors in nuclear extracts as Fl(2)d. As noted above, these factors include Snf, U170k, and the two U2AF subunits U2AF38 and U2AF50. In the case of Snf, we have previously shown that Sxl is in an immunoprecipitable complex with Snf in nuclear extracts. Although this is also true for Fl(2)d, there are some differences in how Fl(2)d and Sxl interact with Snf. For one, Fl(2)d:Snf interactions in nuclear extracts are insensitive to RNase, while Sxl:Snf interactions are RNase sensitive. While we did not test whether Fl(2)d:Snf interactions involve direct protein contacts, both Fl(2)d and Snf can interact directly with Sxl in vitro. Fl(2)d and Sxl also differ in their interactions with the Snf mutant proteins 148 and 5mer. Sxl can associate with the Snf5mer protein, but does not form a complex with Snf148. By contrast, Fl(2)d complex formation with the Snf148 mutant protein appears to be equivalent to that observed for wild-type Snf, while complexes with Snf5mer appear to be destabilized and in our hands are present in reduced yield. In addition, we also found that Sxl resembles Fl(2)d in that it is not stably associated either with the U5 snRNP protein U5-40k or with SKIP.
It has been suggested—on the basis of in vitro splicing experiments using a chimeric pre-mRNA consisting of an adenovirus 5' exon/intron fused to a short sequence spanning the 3' splice site of the Sxl male exon—that Sxl autoregulation depends upon Sxl inhibition of the second catalytic step of splicing, i.e., the joining of the 5' splice site of the Sxl second exon to the 3' splice site of the male exon and the release of the second intron lariat intermediate (LALLENA et al. 2002). In this model, Sxl was proposed to block this catalytic step by inhibiting the SPF45 factor bound to one of the two AG sequences in the male exon 3' splice site. It was suggested that this would force the splicing machinery to bypass the male exon 3' splice site and instead join the free 5' splice site of exon 2 to the 3' splice of exon 4 located slightly more than a kilobase downstream of the male exon. In addition to the fact that using a 3' AG for the second catalytic step that is located
1 kb from the branch point would be highly unusual, it is difficult to reconcile this model for Sxl autoregulation with the results presented here, which argue that Sxl must act at a much earlier point during the initial assembly of the splicing apparatus on target pre-mRNAs. Other findings also seem to be inconsistent with this model. For one, the Sxl-binding sites located in the polypyrimidine tract of the male exon 3' splice site that were used in the in vitro splicing experiments are completely dispensable for female splicing of the Sxl pre-mRNAs in vivo. In fact, the critical sites for Sxl binding are located in the upstream and downstream intron sequences flanking the male exon >200 bases from the male 3' splice site. In addition, Sxl regulation in vivo seems to pivot on blocking the use of the male exon 5' splice site, while controlling the use of the male exon 3' splice site plays at most only a subordinate role in regulation (HORABIN and SCHEDL 1993b). Finally, although SPF45 is present in purified B spliceosome complexes from humans, it is apparently absent from the catalytically active B* and C complexes (JURICA et al. 2002; MAKAROV et al. 2002; DECKERT et al. 2006).
Another question of interest is the nature of the relationship between Sxl and Fl(2)d. Like Snf, Fl(2)d can interact directly with Sxl in vitro. For Snf, the first Sxl RRM domain R1 mediates this interaction while for Fl(2)d the interaction appears to depend upon a combination of the Sxl N terminus and the R1 RRM domain. Although the in vitro interactions between recombinant Sxl and Snf proteins are not dependent on (or stimulated by RNA), RNase treatment completely disrupts Sxl:Snf interactions in nuclear extracts. By contrast, RNase treatment appears to significantly enhance Sxl:Fl(2)d interactions in nuclear extracts. Since the two Sxl RRM domains undergo a substantial rearrangement when they bind to RNA (HUGHSON and SCHEDL 1999), it is possible that Sxl:Fl(2)d interactions occur prior to the binding of the Sxl protein to the pre-mRNA, while Sxl:Snf interactions occur after Sxl has associated with its target sequences. If this is the case, then one plausible idea would be that Fl(2)d helps recruit Sxl into the assembling spliceosome. This mechanism could potentially account for the finding that fl(2)d mutations dominantly suppress the female lethal effects of the antimorphic Nβ-gal trangene: there would be less of Nβ-GAL fusion protein incorporated into the Sxl splicing complex when fl(2)d activity is reduced. However, since we were unable to demonstrate an association between Fl(2)d and the Nβ-GAL fusion protein in vivo, we cannot exclude other mechanisms for suppression and further studies will be required to fully understand how Fl(2)d functions in Sxl-dependent alternative splicing.
Given that Sxl and key cofactors like Fl(2)d associate with early acting general splicing regulators that function to define the 5' and the 3' splice sites, it is possible that Sxl promotes female-specific splicing of its own pre-mRNAs by inhibiting the process of exon definition. Presumably it would do so by specifically targeting the U1 snRNP associated with the male exon 5' splice site and SPF45 and the U2AF heterodimer associated with the male exon 3' splice site. Exon definition is thought to be particularly important when a small exon is surrounded by large introns as is the case for the Sxl male exon. It is only
190 bp in length and is flanked by large introns. Interestingly, exon definition cannot occur for exons >500 nucleotides and, if a large exon is surrounded by large introns, such an exon is often skipped entirely (STERNER et al. 1996; FOX-WALSH et al. 2005). Consistent with these studies, several of the gain-of-function mutations in Sxl are transposon insertions that increase the size of the male exon. In these mutants, Sxl is not required for female-specific splicing and the male exon is skipped, even in the absence of Sxl protein (BERNSTEIN et al. 1995). Also supporting the notion that male exon definition might be an especially sensitive step that would make it a good target for Sxl regulation is the fact that both the 3' and 5' male exon splice sites are known to be suboptimal. In fact, when the male exon (plus the associated splice sites) is placed into a heterologous intron, the male exon is not recognized by the splicing machinery unless the splice sites are optimized to more closely resemble the consensus sequence (HORABIN and SCHEDL l993a). Even then, the male exon is not efficiently recognized by the default splicing machinery and is skipped most of the time. Further studies will be required to explore this possible mechanism for Sxl regulation.
| ACKNOWLEDGEMENTS |
|---|
|
|
|---|
| FOOTNOTES |
|---|
| LITERATURE CITED |
|---|
|
|
|---|
ACHSEL, T., K. AHRENS, H. BRAHAMS, S. TEIGELKAMP and R. LUHRMANN, 1998 The human U5–220kD protein (hPrp8) forms a stable RNA-free complex with several U5-specific proteins, including an RNA unwindase, a homologue of ribosomal elongation factor EF-2, and a novel WD-40 protein. Mol. Cell. Biol. 18: 6756–6766.
BERNSTEIN, M., R. A. LERSCH, L. SUBRAHMANYAN and T. W. CLINE, 1995 Transposon insertions causing constitutive Sex-lethal activity in Drosophila melanogaster affect Sxl sex-specific transcript splicing. Genetics 139: 631–648.[Abstract]
BURNETTE, J. M., A. R. HATTON and A. J. LOPEZ, 1999 Trans-acting factors required for inclusion of regulated exons in the Ultrabithorax mRNAs of Drosophila melanogaster. Genetics 151: 1517–1529.
CHAOUKI, A. S., and H. K. SALZ, 2006 Drosophila SPF45: a bifunctional protein with roles in both splicing and DNA repair. PLoS Genet. 2: 1974–1983.
CLINE, T., and B. MEYER, 1996 Viva la difference: males vs females in flies vs worms. Annu. Rev. Genet. 30: 637–702.[CrossRef][Medline]
DECKERT, J., K. HARTMUTH, D. BOEHRINGER, N. BEHZADNIA, C. L. WILL et al., 2006 Protein composition and electron microscopy structure of affinity-purified human spliceosomal B complexes isolated under physiological conditions. Mol. Cell. Biol. 26: 5528–5543.
DESHPANDE, G., J. STUKEY and P. SCHEDL, 1995 scute (sis-b) function in Drosophila sex determination. Mol. Cell. Biol. 15: 4430–4440.[Abstract]
DESHPANDE, G., M. E. SAMUELS and P. SCHEDL, 1996 Sex-lethal interacts with splicing factors in vitro and in vivo. Mol. Cell. Biol. 16: 5036–5047.[Abstract]
DESHPANDE, G., G. CALHOUN and P. SCHEDL, 1999 The N-terminal domain of Sxl protein disrupts Sxl autoregulation in females and promotes female-specific splicing of tra in males. Development 126: 2841–2853.[Abstract]
FABRIZIO, P., B. LAGGERBAUER, J. LAUBER, W. S. LANE and R. LUHRMANN, 1997 An evolutionarily conserved U5 snRNP-specific protein is a GTP-binding factor closely related to the ribosomal translocase EF-2. EMBO J. 16: 4092–4106.[CrossRef][Medline]
FLICKINGER, T. W., and H. K. SALZ, 1994 The Drosophila sex determination gene snf encodes a nuclear protein with sequence and functional similarity to the mammalian U1A snRNP protein. Genes Dev. 8: 914–925.
FOX-WALSH, K. L., Y. DOU, B. J. LAM, S. P. HUNG, P. F. BALDI et al., 2005 The architecture of pre-mRNAs affects mechanisms of splice-site pairing. Proc. Natl. Acad. Sci. USA 102: 16176–16181.
GRANADINO, B., S. CAMPUZNO and L. SANCHEZ, 1990 The Drosophila melanogaster fl(2)d gene is needed for the female-specific splicing of Sex-lethal RNA. EMBO J. 8: 2597–2602.
GRANADINO, B., A. SAN JUAN, P. SANTAMARIA and L. SANCHEZ, 1992 Evidence of a dual function in fl(2)d, a gene needed for Sex-lethal expression in Drosophila melanogaster. Genetics 130: 597–612.[Abstract]
GRANADINO, B., L. O. PENALVA and L. SANCHEZ, 1996 The gene fl(2)d is needed for the sex-specific splicing of transformer pre-mRNA but not for double-sex pre-mRNA in Drosophila melanogaster. Mol. Gen. Genet. 253: 26–31.[CrossRef][Medline]
HAGER, J. H., and T. W. CLINE, 1997 Induction of female Sex-lethal RNA splicing in male germ cells: implications for Drosophila germline sex determination. Development 124: 5033–5048.[Abstract]
HARTMUTH, K., H. URLAUB, H. P. VORNLOCHER, C. L. WILL, M. GENTZEL et al., 2002 Protein composition of human prespliceosomes isolated by a tobramycin affinity-selection method. Proc. Natl. Acad. Sci. USA 99: 16719–16724.
HORABIN, J., and P. SCHEDL, 1993a Regulated splicing of the Drosophila Sex-lethal male exon involves a blockage mechanism. Mol. Cell. Biol. 13: 1408–1414.
HORABIN, J., and P. SCHEDL, 1993b Sex-lethal autoregulation requires multiple cis-acting elements upstream and downstream of the male exon and appears to depend largely on controlling the use of the male exon 5' splice site. Mol. Cell. Biol. 13: 7734–7746.
HUGHSON, F. M., and P. SCHEDL, 1999 Two domains and one RNA: a molecular threesome. Nat. Struct. Biol. 6: 499–502.[CrossRef][Medline]
JURICA, M. S., and M. J. MOORE, 2003 Pre-mRNA splicing: awash in a sea of proteins. Mol. Cell 12: 5–14.[CrossRef][Medline]
JURICA, M. S., L. J. LICKLIDER, S. R. GYGI, N. GRIGORIEFF and M. J. MOORE, 2002 Purification and characterization of native spliceosomes suitable for three-dimensional structural analysis. RNA 8: 426–439.[Abstract]
LALLENA, M. J., K. J. CHALMERS, S. LLAMAZARES, A. I. LAMOND and J. VALCARCEL, 2002 Splicing regulation at the second catalytic step by Sex-lethal involves 3' splice site recognition by SPF45. Cell 109: 285–296.[CrossRef][Medline]
MAKAROV, E. M., O. V. MARKAROVA, H. URLAUB, M. GENTZEL, C. L. WILL et al., 2002 Small nuclear ribonucleoprotein remodeling during catalytic activation of the spliceosome. Science 298: 2205–2208.
NAGENGAST, A. A., S. M. STITZINGER, C. H. TSENG, S. M. MOUNT and H. K. SALZ, 2003 Sex-lethal splicing autoregulation in vivo: interactions between SEX-LETHAL, the U1 snRNP and U2AF underlie male exon skipping. Development 130: 463–471.
ORTEGA, A., M. NIKSIC, A. BACHI, M. WILM, L. SANCHEZ et al., 2003 Biochemical function of female-lethal (2)D/Wilms' tumor suppressor-1-associated proteins in alternative pre-mRNA splicing. J. Biol. Chem. 278: 3040–3047.
PENALVA, L. O., M. F. RUIZ, A. ORTEGA, B. GRANADINO, L. VICENTE et al., 2000 The Drosophila fl(2)d gene, required for female-specific splicing of Sxl and tra pre-mRNAs, encodes a novel nuclear protein with a HQ-rich domain. Genetics 155: 129–139.
POLYCARPOU-SCHWARZ, M., S. I. GUNDERSON, S. KADELS-LEWIS, B. SERAPHIN and I. W. MATTAJ, 1996 Drosophila SNF/D25 combines the functions of the two snRNP proteins U1A and U2B' that are encoded separately in human, potato, and yeast. RNA 2: 11–23.[Abstract]
REED, R., 2000 Mechanisms of fidelity in pre-mRNA splicing. Curr. Opin. Cell Biol. 12: 340–345.[CrossRef][Medline]
RUDNER, D. Z., R. KANAAR, K. S. BREGER and D. C. RIO, 1996 Mutations in the small subunit of the Drosophila U2AF splicing factor cause lethality and developmental defects. Proc. Natl. Acad. Sci. USA 93: 10333–10337.
RUDNER, D. Z., K. S. BREGER, R. KANAAR, M. D. ADAMS and D. C. RIO, 1998 RNA binding activity of heterodimeric splicing factor U2AF: at least one RS domain is required for high-affinity binding. Mol. Cell. Biol. 18: 4004–4011.
SALZ, H. K., and T. W. FLICKINGER, 1996 Both loss-of-function and gain-of-function mutations in snf define a role for snRNP proteins in regulating Sex-lethal pre-mRNA splicing in Drosophila development. Genetics 144: 95–108.[Abstract]
SAMUELS, M. E., D. BOPP, R. A. COLVIN, R. F. ROSCIGNO, M. A. GARCIA-BLANCO et al., 1994 RNA binding by Sxl proteins in vitro and in vivo. Mol. Cell. Biol. 14: 4975–4990.
SAMUELS, M., G. DESHPANDE and P. SCHEDL, 1998 Activities of the Sex-lethal protein in RNA binding and protein:protein interactions. Nucleic Acids Res. 26: 2625–2637.
SOSNOWSKI, B. A., J. M. BELOTE and M. MCKEOWN, 1989 Sex-specific alternative splicing of RNA from the transformer gene results from sequence-dependent splice site blockage. Cell 58: 449–459.[CrossRef][Medline]
STARK, H., and R. LUHRMANN, 2006 Cryo-electron microscopy of spliceosomal components. Annu. Rev. Biophys. Biomol. Struct. 35: 435–457.[CrossRef][Medline]
STERNER, D. A., T. CARLO and S. M. BERGET, 1996 Architectural limits on split genes. Proc. Natl. Acad. Sci. USA 93: 15081–15085.
STITZINGER, S. M., T. R. CONRAD, A. M. ZACHLIN and H. K. SALZ, 1999 Functional analysis of SNF, the Drosophila U1A/U2B'' homolog: identification of dispensable and indispensable motifs for both snRNP assembly and function in vivo. RNA 5: 1440–1450.[Abstract]
TAN, L., J. S. CHANG, A. COSTA and P. SCHEDL, 2001 An autoregulatory feedback loop directs the localized expression of the Drosophila CPEB protein Orb in the developing oocyte. Development 128: 1159–1169.[Abstract]
VALCARCEL, J., R. SINGH, P. D. ZAMORE and M. R. GREEN, 1993 The protein Sex-lethal antagonizes the splicing factor U2AF to regulate alternative splicing of transformer pre-mRNA. Nature 362: 171–175.[CrossRef][Medline]
YANOWITZ, J. L., G. DESHPANDE, G. CALHOUN and P. D. SCHEDL, 1999 An N-terminal truncation uncouples the sex-transforming and dosage compensation functions of sex-lethal. Mol. Cell. Biol. 19: 3018–3028.
ZHANG, C., D. R. DOWD, A. STAAL, C. GU, J. B. LIAN et al., 2003 Nuclear coactivator-62 kDa/Ski-interacting protein is a nuclear matrix-associated coactivator that may couple vitamin D receptor-mediated transcription and RNA splicing. J. Biol. Chem. 278: 35325–35336.
ZHOU, Z., L. J. LICKLIDER, S. P. GYGI and R. REED, 2002 Comprehensive proteomic analysis of the human spliceosome. Nature 419: 182–185.[CrossRef][Medline]
Communicating editor: J. A. BIRCHLERRelated articles in Genetics:
This article has been cited by other articles:
![]() |
S. Zhong, H. Li, Z. Bodi, J. Button, L. Vespa, M. Herzog, and R. G. Fray MTA Is an Arabidopsis Messenger RNA Adenosine Methylase and Interacts with a Homolog of a Sex-Specific Splicing Factor PLANT CELL, May 1, 2008; 20(5): 1278 - 1288. [Abstract] [Full Text] [PDF] |
||||
| ||||||